These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10937982)

  • 41. Lack of effect of nitrates on exercise tolerance in patients with mild to moderate heart failure caused by coronary disease already treated with captopril.
    Wieshammer S; Hetzel M; Hetzel J; Kochs M; Hombach V
    Br Heart J; 1993 Jul; 70(1):17-21. PubMed ID: 8037993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Captopril therapy for heart failure. A placebo controlled study.
    Cowley AJ; Rowley JM; Stainer KL; Hampton JR
    Lancet; 1982 Oct; 2(8301):730-2. PubMed ID: 6125809
    [No Abstract]   [Full Text] [Related]  

  • 43. Inhibitors of angiotensin-converting enzyme and physical function in older women.
    Cicoira M
    Lancet; 2002 Oct; 360(9339):1099; author reply 1099-100. PubMed ID: 12384018
    [No Abstract]   [Full Text] [Related]  

  • 44. Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure.
    Motwani JG; Lang CC; Allen MJ; Johnson HF; Struthers AD
    Clin Pharmacol Ther; 1993 Dec; 54(6):661-9. PubMed ID: 8275621
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Failure of "effective" treatment for heart failure to improve normal customary activity.
    Walsh JT; Andrews R; Evans A; Cowley AJ
    Br Heart J; 1995 Oct; 74(4):373-6. PubMed ID: 7488449
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism.
    Lang CC; Motwani JG; Coutie WJ; Struthers AD
    Clin Sci (Lond); 1992 Jun; 82(6):619-23. PubMed ID: 1320540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-dose but not high-dose captopril increases parasympathetic activity in patients with heart failure.
    Kamen PW; Krum H; Tonkin AM
    J Cardiovasc Pharmacol; 1997 Jul; 30(1):7-11. PubMed ID: 9268215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the effects of captopril and enoximone in patients with severe heart failure: a placebo controlled double-blind study.
    Cowley AJ; Stainer K; Wynne RD; Rowley JM; Hampton JR
    Int J Cardiol; 1989 Sep; 24(3):311-6. PubMed ID: 2527829
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease.
    Wilkins MR
    Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):673-8. PubMed ID: 8224488
    [No Abstract]   [Full Text] [Related]  

  • 50. Skeletal muscle depressed calcium and phosphofructokinase in chronic heart failure are upregulated by captopril--a double-blind, placebo-controlled study.
    Sylvén C; Jansson E; Cederholm T; Hildebrand IL; Beermann B
    J Intern Med; 1991 Feb; 229(2):171-4. PubMed ID: 1825503
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Converting enzyme inhibition and heart failure.
    Magnani B
    Am J Med; 1988 Mar; 84(3A):87-91. PubMed ID: 3064604
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Captopril treatment of chronic heart failure in the very old.
    De Bock V; Mets T; Romagnoli M; Derde MP
    J Gerontol; 1994 May; 49(3):M148-52. PubMed ID: 8169337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison of the effects of captopril and flosequinan in patients with severe heart failure.
    Cowley AJ; Wynne RD; Swami A; Birkhead J; Skene A; Hampton JR
    Cardiovasc Drugs Ther; 1992 Oct; 6(5):465-70. PubMed ID: 1450090
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure.
    Richardson A; Bayliss J; Scriven AJ; Parameshwar J; Poole-Wilson PA; Sutton GC
    Lancet; 1987 Sep; 2(8561):709-11. PubMed ID: 2888942
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potential role of mixed ACE and neutral endopeptidase inhibitor in the treatment of heart failure.
    Hu K; Ertl G
    Cardiovasc Res; 1999 Mar; 41(3):503-5. PubMed ID: 10435019
    [No Abstract]   [Full Text] [Related]  

  • 56. Angiotensin-converting enzyme inhibition in mild to moderate congestive heart failure: an evolving approach.
    Massie BM
    Am J Hypertens; 1988 Oct; 1(4 Pt 2):402S-409S. PubMed ID: 3056452
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fasidotril. Aladotril, alatriopril, BP 1137.
    Drugs R D; 1999 Apr; 1(4):346-7. PubMed ID: 10566060
    [No Abstract]   [Full Text] [Related]  

  • 58. MDL 100240.
    Drugs R D; 1999 Apr; 1(4):348-9. PubMed ID: 10566061
    [No Abstract]   [Full Text] [Related]  

  • 59. Angiotensin converting enzyme inhibition improves cerebrovascular control during exercise in male rats with heart failure.
    Butenas ALE; Colburn TD; Baumfalk DR; Ade CJ; Hageman KS; Copp SW; Poole DC; Musch TI
    Respir Physiol Neurobiol; 2021 Apr; 286():103613. PubMed ID: 33421609
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of candoxatril on plasma brain natriuretic peptide in heart failure.
    Lang CC; Motwani J; Coutie WJ; Struthers AD
    Lancet; 1991 Jul; 338(8761):255. PubMed ID: 1676808
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.